External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ACTRIMS-ECTRIMS 2020

-
Coming soon
01:00 PM
Duration 12mins Virtual
Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the Phase III SAkura studies
Jacqueline Palace, Ingo Kleiter, Anthony Traboulsee, Takashi Yamamura, Francesco Patti, Daniela Stokmaier, Gaëlle Klingelschmitt, Thomas Kuenzel, H.-Christian von Büdingen, Jeffrey L. Bennett

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 12mins Virtual
Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO
DL Arnold, T Sprenger, A Bar-Or, J Wolinsky, L Kappos, S Kolind, HM Schneble, S Magon, J van Beek, H Koendgen, C Bernasconi, L Gaetano, A Traboulsee

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 AM
Duration 12mins Virtual
COVID-19 in persons with multiple sclerosis treated with ocrelizumab▼: pharmacovigilance update
R Hughes, K Fitovski, L Whitley, N Jessop, H-M Schneble, E Muros-Le Rouzic, A Sauter, R Pedotti, H Koendgen

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar